Across TCGA pan-cancer cohorts, RAB7A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RAB7A data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher RAB7A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB7A expression acts as an unfavorable survival marker.
COAD are the cancer types where RAB7A Mutation most reproducibly stratifies survival.